Mutations in human insulin3 Leu. By analogy to the nomenclature describing abnormal hemoglobins, these are designated insulins Wakayama, Los Angeles, and Chicago, respectively (1). We demonstrate here that these mutations occur at contact sites between insulin and the ␣-subunit of the insulin receptor.The structure of insulin is well characterized by crystallography (3) and nuclear magnetic resonance spectroscopy (4,5) (Fig. 1A). Residues A3, B24, and B25 exhibit distinct environments. Whereas Phe B25 projects from the surface, Val A3 and Phe B24 are engaged in long-range interactions (Fig. 2). Val A3 contacts Tyr B26 and Pro B28 at an interface between the NH 2 -terminal A-chain ␣-helix and COOH-terminal B-chain -strand (Fig. 2B) , Tyr B16 , and Cys B19 to stabilize the supersecondary structure of the B-chain. In dimers and hexamers, Phe B24 and Phe B25 also participate in an intermolecular -sheet, an essential element of insulin's storage form in the -cell (3). Whereas considerable evidence indicates that the exposed side chain of Phe B25 contacts the insulin receptor (6, including previous photo crosslinking studies [7,8]), the roles of Val A3 and Phe B24 have long been the subject of speculation (3,9 -13).To test whether residues A3, B24, and B25 contact the insulin receptor, we have synthesized insulin analogs containing a photo-activatable derivative of phenylalanine (Phe), para-azido-Phe (Pap) (8,14). Pap was chosen based on its rigidity and small size (relative to other photoactivable moieties), thus limiting the distance range for cross-linking. Modified A-and B-chains were prepared by solid-phase synthesis using the photostable precursor para-amino-Phe. To enable efficient detection of crosslinked peptides, the ␣-amino group of the B-chain was biotinylated (8). The nonstandard side chain was introduced into an engineered insulin monomer (DKP-insulin, which contains three B-chain substitutions: His B10 3 Asp, Pro B28 3 Lys, and Lys B29 3 Pro), chosen as a template for its efficiency of synthesis, enhanced receptor binding, and absence of confounding self-association (4). A3, B24, and B25 para-amino-Phe analogs exhibit respective receptorbinding affinities of 2.0 Ϯ 0.2, 59 Ϯ 2, and 147 Ϯ 3% relative to native insulin (K d 0.48 nmol/l); the affinity of the biotin adduct of DKP-insulin is 132 Ϯ 5% (assays performed in triplicate). Corresponding analogs were prepared at terminal positions A1 and A21 (ordinarily conserved as Gly and Asn, respectively) at the periphery of insulin's putative receptor-binding surface (3,15); their relative receptorbinding affinities are 46 Ϯ 5 and 79 Ϯ 22%. Asn A21 projects from the surface near Gly B23 and Phe B25 ( Fig. 2A). Conversion of para-amino-Phe to Pap in the intact hormones was verified by mass spectrometry.